UK-based F-star Therapeutics has lined up multiple partners and Big Pharma licensing deals since snagging the Fierce 15 in 2011, but the latest pact with Johnson & Johnson is the biggest yet. The deal includes a modest $17.5 million upfront for up to five F-star bispecific antibodies, with a backloaded $1.35 billion in biobucks on the line. J&J's pharma unit Janssen snags the exclusive worldwide license to research, develop and commercialize those assets directed at targets of its choice, F-star said Wednesday. Source: Fierce Biotech 20/10/2021